NASDAQ · Biotechnology · USD
Obsidian Therapeutics, Inc. (OBX) Stock Analysis
Obsidian Therapeutics, Inc. (OBX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
OBX Key Statistics
As of Oct 21, 2026Trading
- Open
- $13.34
- Previous Close
- $13.25
- Day's Range
- 13.34–14.60
- 52-Week Range
- 11.52–49.97
- Volume
- 332.84K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 2.64
Valuation
- Market Cap
- $860.50M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −1.63
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$100.61M
- Shares Outstanding
- 61.77M
Dividend and dates
- Avg Volume
- 363.16K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
Obsidian Therapeutics, Inc. (OBX) has a market capitalization of $860.50M.
In fiscal 2025, OBX reported revenue of $0.00.
OBX Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$100.61M | — |
| 2024 | $0.00 | −$83.11M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$105.67M | −$100.61M | — |
| 2024 | $0.00 | — | −$91.26M | −$83.11M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting
YahooObsidian Therapeutics To Present Updated Data In Patients With Immune-Checkpoint Inhibitor-Resistant Advanced Melanoma From Its Phase 1 Study And The Phase 1/2 Agni-01 Multicenter Study Of Amsokigene Autoleucel
BenzingaLeerink Partners Initiates Coverage On Obsidian Therapeutics with Outperform Rating, Announces Price Target of $32
BenzingaObsidian Therapeutics: A $1.1 Billion Valuation Leaves Little Margin For Error
SeekingAlphaObsidian Therapeutics Files Prospectus Related To Resale Of Up To 29,164,045 Shares Of Common Stock By Selling Stockholders
BenzingaObsidian Therapeutics Enrolls First Participant In Its Phase 1/2 Agni-01 Trial Of Amsokigene Autoleucel To Treat Advanced Or Metastatic Melanoma
Benzinga
All 7 articles ↓Show fewer ↑
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B